Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference62 articles.
1. Estrin S, Prevezer M. A survey on institutions and new firm entry: how and why do entry rates differ in emerging markets? Econ Syst. 2010;34(3):289–308.
2. Ades F, Zardavas D, Senterre C, de Azambuja E, Eniu A, Popescu R, et al. Hurdles and delays in access to anti-cancer drugs in Europe. Ecancermedicalscience. 2014;8:482–91.
3. Lundkvist J, Jönsson B, Rehnberg C. The costs and benefits of regulations for reimbursement of new drugs. Health Policy. 2006;79(2):337–44.
4. European Medicines Agency. European public assessment reports. 2018. Website. https://www.ema.europa.eu/en/medicines/ema_group_types/ema_medicine. Accessed 22 Dec 2022.
5. Department of Health. National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations. UK Legislation. 2013. No. 259. Available from: https://www.legislation.gov.uk/uksi/2013/259/contents/made. Accessed 22 Dec 2022.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献